Roble, Belko & Company, Inc Sarepta Therapeutics, Inc. Transaction History
Roble, Belko & Company, Inc
- $627 Million
- Q1 2025
A detailed history of Roble, Belko & Company, Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 8 shares of SRPT stock, worth $303. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8
Previous 8
-0.0%
Holding current value
$303
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SRPT
# of Institutions
507Shares Held
88.9MCall Options Held
1.39MPut Options Held
1.13M-
Black Rock Inc. New York, NY10.3MShares$392 Million0.04% of portfolio
-
Capital International Investors Los Angeles, CA9.06MShares$344 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.03MShares$343 Million0.01% of portfolio
-
State Street Corp Boston, MA4.07MShares$154 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$128 Million0.12% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $3.32B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...